PlainPill

GLP-1S

People mainly take GLP-1S for weight loss. Based on 4 first-hand reports and 6 meta-analyses & systematic reviews in the medical literature. Ranked #1992 of 3,539 overall.

14
User score
Mostly positive
25% positive0% mixed0% negative75% unclear

Of reports that state an outcome, 100% are positive.

Clinical research
BModerate research base
6
meta-analyses
6
RCTs
191
papers

What GLP-1S does, according to users

Of the people who reported each effect, the share who said it got better.

betterno changeworse

What the research says

Systematic reviews and meta-analyses from PubMed, with their published conclusions.

BModerate research base

At least one meta-analysis, or 5+ randomized controlled trials. The grade measures how much human research exists — read the conclusions below for what it found.

Brain Inj · 2019 · Meta-analysis / systematic review
GLP-1's role in neuroprotection: a systematic review

Conclusion: Conclusion: Based on the preclinical studies, GLP-1 modifying agents are promising targets for neuroprotection. On the other hand, the number of clinical studies that investigate GLP-1 as a treatment is low and further clinical trials are needed for a benchside to bedside translation of recent findings.

PubMed 30938196 ↗
Acta Neuropsychiatr · 2025 · Meta-analysis / systematic review
A systematic review on the role of glucagon-like peptide-1 receptor agonists on alcohol-related behaviors: potential therapeutic strategy for alcohol use disorder

Conclusion: Extant preclinical and clinical literature provides preliminary support for the potential therapeutic role of GLP-1RAs in attenuating alcohol consumption and preference. There is a need for large well controlled studies evaluating the effect of GLP-1RAs as a treatment strategy for behavioural modifications in individuals living with alcohol use disorder.

PubMed 39969054 ↗
Diabetes Res Clin Pract · 2012 · Meta-analysis / systematic review
Cardiovascular safety and glycemic control of glucagon-like peptide-1 receptor agonists for type 2 diabetes mellitus: a pairwise and network meta-analysis

Conclusion: Our network meta-analysis provides a complete picture of the associations between GLP-1s, ACD and placebo on CVD safety and glycemic control. The GLP-1s are promising candidates for the treatment of T2DM, but more long-term trials are needed to confirm potential CVD safety.

PubMed 23020934 ↗

Dosage people report

As stated by users — not a recommendation. Follow the label or your doctor.

No doses stated in the reports so far.

Reported side effects

How often each side effect came up across all reports.

No side effects reported so far.

What users say

First-hand experiences, quoted verbatim. We show one positive and one negative where both exist.

Other options for weight loss

User data from public discussions; research from PubMed. Information only, not medical advice — talk to a doctor before starting, stopping or combining anything. Data updated October 3, 2026. How we rate